Skip to main content

Advertisement

ADVERTISEMENT

Peer Review

Peer Reviewed

Brief Contribution

Adverse Events With Intravascular Lithotripsy After Peripheral and Off-Label Coronary Use: A Report From the FDA MAUDE Database

Yashasvi Chugh, MD1;  Jaikirshan J. Khatri, MD2;  Mehdi H. Shishehbor, DO, MPH, PhD3;  Subhash Banerjee, MD4;  Kevin Croce, MD5;  Khaldoon Alaswad, MD6;  Bilal Murad, MD1;  Santiago Garcia, MD1;  M. Nicholas Burke, MD1;  Emmanouil S. Brilakis, MD, PhD1

December 2021
1557-2501
J INVASIVE CARDIOL 2021;33(12):E974-E977. doi:10.25270/jic/21.00034

1. Hill JM, Kereiakes DJ, Shlofmitz RA, et al. Intravascular lithotripsy for treatment of severely calcified coronary artery disease. J Am Coll Cardiol. 2020;76:2635-2646.

2. Brodmann M, Werner M, Brinton TJ, et al. Safety and performance of lithoplasty for treatment of calcified peripheral artery lesions. J Am Coll Cardiol. 2017;70:908-910.

3. Brodmann M, Werner M, Holden A, et al. Primary outcomes and mechanism of action of intra-vascular lithotripsy in calcified, femoropopliteal lesions: results of Disrupt PAD II. Catheter Cardiovasc Interv. 2019;93:335-342.

4. Adams G, Shammas N, Mangalmurti S, et al. Intravascular lithotripsy for treatment of calcified lower extremity arterial stenosis: initial analysis of the Disrupt PAD III study. J Endovasc Ther. 2020;27:473-480.

5. Brodmann M, Holden A, Zeller T. Safety and feasibility of intravascular lithotripsy for treatment of below-the-knee arterial stenoses. J Endovasc Ther. 2018;25:499-503.


Advertisement

Advertisement

Advertisement